8-K
false 0001422142 0001422142 2021-08-17 2021-08-17 0001422142 dei:FormerAddressMember 2021-08-17 2021-08-17

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): August 17, 2021

 

 

AERPIO PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-38560   61-1547850

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

c/o 10663 Loveland-Madeira Road #168

Loveland, OH

  45140
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code (513) 985-1920

 

9987 Carver Road

Cincinnati, OH

  45242
  (Zip Code)

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common stock, $0.0001 par value per share   ARPO   Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

 

 

 


Item 1.01.

Entry into a Material Definitive Agreement.

Asset Purchase Agreement

On August 17, 2021, Aerpio Pharmaceuticals, Inc. (the “Company”) entered into an Asset Purchase Agreement (the “Purchase Agreement”) with EyePoint Pharmaceuticals, Inc. (“EyePoint”) pursuant to which the Company agreed to sell all of the Company’s right, title and interest in and to the patents and patent applications related to (a) the Phase 2 program for razuprotafib in glaucoma, (b) the Phase 2 program of razuprotafib in COVID-19, and (iii) Preclinical Tie2 activating antibodies in return for a one-time cash payment of $450,000. The closing of the Purchase Agreement is contingent upon and effective after the closing of the merger of the Company with Aadi Bioscience, Inc., as approved by the stockholders of the Company on August 17, 2021, and as previously described in the Company’s Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the “SEC”) on May 17, 2021.

The foregoing description of the Purchase Agreement is not complete and is qualified in its entirety by reference to the full text of the Purchase Agreement, which is attached as Exhibit 10.1 hereto and incorporated herein by reference.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit
No.
  

Description

10.1    Asset Purchase Agreement dated August 17, 2021, by and between Aerpio Pharmaceuticals, Inc. and EyePoint Pharmaceuticals, Inc. (filed herewith).*
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

*

Certain exhibits and schedules to the Purchase Agreement have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the SEC upon request.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: August 23, 2021     AERPIO PHARMACEUTICALS, INC.
    By:  

/s/ Joseph Gardner, Ph.D.

      Joseph Gardner
      President and Founder
EX-10.1

Exhibit 10.1

ASSET PURCHASE AGREEMENT

This ASSET PURCHASE AGREEMENT (the “Agreement”) is entered into as of August 17, 2021 (the “Effective Date”), by and between Aerpio Pharmaceuticals, Inc., a Delaware corporation on behalf of itself and its wholly-owned subsidiaries (“Seller”), and EyePoint Pharmaceuticals, Inc., a Delaware corporation (“Purchaser”).

RECITALS

WHEREAS, Seller desires to sell, assign, transfer, convey and deliver to Purchaser, and Purchaser desires to purchase, acquire and accept from Seller, the Transfer Assets (as defined below), upon the terms and subject to the conditions hereinafter set forth.

AGREEMENT

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Purchaser and Seller hereby agree as follows:

1. Sale of Transfer Assets. Upon the terms and subject to the conditions of this Agreement, in consideration of and in exchange for the consideration set forth in Sections 3, Seller agrees, on the Closing Date (as defined below), to sell, transfer, assign and convey to Purchaser, and Purchaser hereby agrees to purchase, acquire and accept from Seller, all of Seller’s right, title and interest in and to the Transfer Assets (as defined below) “as is”, “where is”, and without recourse (except as expressly set forth in this Agreement), and (except as set forth in Section 8 below) without representations or warranties of any kind, express or implied, including, without limitation, any warranties as to quiet enjoyment, merchantability, value, useful life, fitness for intended use, or similar representations and warranties. On the Closing Date, Seller and Purchaser shall execute and deliver to each other a Bill of Sale, substantially in the form attached hereto as Exhibit A, and a Patent Assignment, substantially in the form attached hereto as Exhibit D. For purposes of this Agreement, “Transfer Assets” shall mean the following:

(a) the patents and patent applications listed on Exhibit B attached hereto (the “Patents”).

2. Excluded Assets. Notwithstanding anything to the contrary in this Agreement, the Transfer Assets shall not include any of the Excluded Assets and the Excluded Assets shall not be transferred to Purchaser, but shall be retained by Seller. For purposes of this Agreement, “Excluded Assets” shall include all assets of Seller not expressly listed as “Transfer Assets”, including without limitation the following items:

(a) all cash, cash equivalents and uncashed checks held or received by Seller prior to the Closing Date;


(b) any right that Seller has with respect to tax refunds, claims for tax refunds and tax attributes arising prior to the Closing Date;

(c) except as otherwise expressly set forth herein, all books and records of the Seller;

(d) the rights or obligations granted to the Seller under this Agreement;

(e) any rights or claims under any insurance policies of the Seller; and

(f) any claims or causes of action arising from or relating to the Seller’s use, ownership or operation of the Transfer Assets prior to the Closing, other than claims for infringement or misappropriation of the Patents and other intellectual property rights included in the Transfer Assets.

3. Consideration. As consideration for the sale, transfer, assignment and conveyance to Purchaser of the Transfer Assets on the Closing Date, Purchaser shall, within one business day following the Effective Date, pay Seller a one-time, non-refundable (except as provided in Section 14(n)), non-creditable payment of Four Hundred Fifty Thousand Dollars ($450,000) (the “Purchase Amount”). Upon Seller’s receipt of the Purchase Amount, the Purchase Amount shall be held in escrow pursuant to the terms of the Joint Escrow Instructions attached to this Agreement as Exhibit E. On the Effective Date, Purchaser and Seller shall execute and deliver to the individual designated as the escrow agent in the Joint Escrow Instructions or person’s designee (the “Escrow Agent”) the Joint Escrow Instructions, which will be held and used by the Escrow Agent pursuant to the terms of the Joint Escrow Instructions. For the avoidance of doubt, the Joint Escrow Instructions provide that the Purchaser and Seller shall instruct the Escrow Agent to release the Purchase Amount to Seller following the satisfaction or waiver of the conditions precedent set forth in Sections 6 and 7.

4. Obligations Assumed.

(a) Liabilities. Purchaser agrees, upon consummation of, and effective as of, the Closing, to assume all liabilities, obligations and commitments of Seller of any nature whatsoever under or related the Transfer Assets, other than liabilities arising out of or relating to conduct accruing prior to the Closing Date (collectively, the “Assumed Liabilities”).

(b) Liabilities and Obligations Not Assumed. Except for the Assumed Liabilities, Purchaser shall not assume or become obligated in any way to pay any liabilities, debts or obligations of Seller whatsoever, including but not limited to any liabilities or obligations now or hereafter arising from Seller’s business activities that took place prior to the Closing or any liabilities arising out of or connected to any action or inaction of Seller in connection with the liquidation and winding down of Seller’s business. All liabilities, debts and obligations of Seller not expressly assumed by Purchaser hereunder as Assumed Liabilities are hereinafter referred to as the “Excluded Liabilities.”

 

2


(c) No Obligations to Third Parties. The execution and delivery of this Agreement shall not be deemed to confer any rights upon any person or entity other than the parties hereto, or make any person or entity a third party beneficiary of this Agreement, or to obligate either party to any person or entity other than the parties to this Agreement. Assumption by Purchaser of any liabilities or obligations of Seller under Section 4(a) shall in no way expand the rights or remedies of third parties against Purchaser as compared to the rights and remedies such parties would have against Seller if the Closing were not consummated.

5. Closing. The closing of the purchase and sale of the Transfer Assets (the “Closing”) shall occur promptly following the satisfaction or waiver of the conditions precedent set forth in Sections 6 and 7 below at such time and place as Seller and Purchaser mutually agree, orally or in writing, and may be effected by the email or facsimile exchange of closing deliverables hereunder (or in such other manner, as the parties shall mutually agree in writing). The date on which the Closing is consummated is referred to herein as the “Closing Date.” Assets meeting the definition of Transfer Assets delivered to Purchaser by or on behalf of Seller either on or after the Closing Date shall be deemed to be Transfer Assets for all purposes of this Agreement.

(a) With respect to the materials listed on Exhibit C attached hereto (the “Materials”), each of Seller and Purchaser shall use commercially reasonable efforts (A) to endeavor to obtain the consents, approvals, clearances, ratifications, permissions, authorizations or waivers from any third parties that control the Materials to cause Purchaser to take title or assume (as applicable) the Materials as of and subject to the Closing (provided that neither Seller nor Purchaser shall be required to expend money, commence, defend or participate in any litigation or offer or grant any accommodation (financial or otherwise) to any such third party), and (B) to cooperate, upon written request of Purchaser, in endeavoring to obtain for Purchaser, at no cost to Seller, an arrangement to provide to the Purchaser, in compliance with law, substantially comparable interests in the Materials as held by Seller immediately prior to the closing. For avoidance of doubt, Seller shall be deemed to have satisfied its obligations under the preceding sentence if, on or before the Closing Date:

i. With respect to the Materials under the heading “Singota Materials,” Seller shall have delivered a Letter of Assignment, in the form previously delivered to Purchaser and signed by the Seller, to the possessor of such Materials.

ii. With respect to the Materials under the heading “Aroz Technologies Materials,” Seller shall have delivered a Letter of Assignment, in the form previously delivered to Purchaser and signed by the Seller, to the possessor of such Materials.

iii. With respect to the Materials under the heading “Charles River Materials,” Seller shall have delivered a Letter of Assignment, in the form previously delivered to Purchaser and signed by the Seller, to the possessor of such Materials.

iv. With respect to the Materials under the heading “Intrinsik IND Materials,” Seller shall have delivered letters to the FDAs in substantially the form attached hereto as Exhibit F-1 and Exhibit F-2, duly executed by Seller, providing notification of the transfer to the Purchaser of all rights of the Seller in and to such Materials.

v. With respect to the Materials under the heading “Intrinsik Other Materials,” Seller shall have delivered a Letter of Assignment, in the form previously delivered to Purchaser and signed by the Seller, to the possessor of such Materials.

 

3


vi. With respect to the Materials under the heading “SDC Materials,” Seller shall have delivered a Letter of Assignment, in the form previously delivered to Purchaser and signed by the Seller, to the possessor of such Materials.

vii. With respect to the Materials under the heading “MedPace Materials,” Seller shall have delivered a Letter of Assignment, in the form previously delivered to Purchaser and signed by the Seller, to the possessor of such Materials.

viii. With respect to the Materials under the heading “Experis Materials,” Seller shall have delivered a Letter of Assignment, in the form previously delivered to Purchaser and signed by the Seller, to the possessor of such Materials.

ix. With respect to the Materials under the heading “Iron Mountain Materials,” Seller shall have delivered a Letter of Assignment, in the form previously delivered to Purchaser and signed by the Seller, or such other documentation as may be appropriate to convey the Iron Mountain Materials to Purchaser at Closing, to the possessor of such Materials.

x. With respect to the Materials under the heading “Electronic Records,” Seller shall have made such Materials available for download by Purchaser.

(b) Following the Effective Date and prior to the Closing, Seller will make available to Purchaser some or all of the Materials and such Materials shall be deemed to be Confidential Information under that certain Bilateral Confidentiality and Non-Disclosure Agreement, dated March 23, 2021, between Seller and Purchaser. In the event that this Agreement is terminated prior to Closing, promptly following such termination, Purchaser shall destroy or return to Seller, at Seller’s sole discretion, any Materials delivered or made available to Purchaser in accordance with Seller’s instructions.

6. Sellers Conditions Precedent. Seller’s obligations to consummate the Closing shall be conditioned upon the satisfaction or waiver of the following:

(a) The representations and warranties of Purchaser contained in Section 9 shall be true on and as of Closing.

(b) The Purchaser shall have performed or complied with all agreements, obligations and conditions contained in this Agreement that are required to be performed or complied with by the Purchaser on or before the Closing.

(c) The Seller shall have consummated a merger with Aspen Merger Subsidiary, Inc., a Delaware corporation (the “Merger”).

(d) The Purchaser shall have executed and delivered to the Escrow Agent the Joint Escrow Instructions in the form attached as Exhibit E hereto.

(e) As of the Closing Date, the sale of the Transfer Assets by Seller or any of the transactions contemplated hereby are not prohibited by any stay or injunction in any litigation, governmental action, or other proceeding, including, without limitation, the “automatic stay” under 11 U.S.C. § 362 in any pending case under Title 11 of the United States Code by or against Seller.

 

4


7. Purchasers Conditions Precedent. Purchaser’s obligations to consummate the Closing shall be conditioned upon the satisfaction or waiver of the following:

(a) The representations and warranties of Seller contained in Section 8 shall be true on and as of Closing.

(b) The Seller shall have performed or complied with all agreements, obligations and conditions contained in this Agreement and required to be performed or complied with by it on or before the Closing, including, but not limited to, Seller’s obligations pursuant to Section 5(a).

(c) As of the Closing Date, the sale of the Transfer Assets by Seller or any of the transactions contemplated hereby are not prohibited by any stay or injunction in any litigation, governmental action, or other proceeding, including, without limitation, the “automatic stay” under 11 U.S.C. § 362 in any pending case under Title 11 of the United States Code by or against Seller.

(d) The Seller shall have executed and delivered to the Escrow Agent the Joint Escrow Instructions in the form attached as Exhibit E hereto.

(e) The Seller shall have executed and delivered to Purchaser a Bill of Sale in the form attached as Exhibit A hereto and a Patent Assignment in the form attached hereto as Exhibit D, with respect to the Transfer Assets.

8. Representations and Warranties of Seller. Except as to Seller’s representations and warranties expressly provided below, the Transfer Assets are being sold “as is,” and “where is” with no express or implied representations or warranties of any kind, nature, or type whatsoever from or on behalf of, Seller. For purposes of this Agreement, the “Knowledge of Seller” means the actual knowledge of Seller, without any duty of inquiry.

(a) Seller (i) is a corporation duly organized, validly existing, and in good standing under the laws of its jurisdiction of incorporation and (ii) has all requisite corporate power and authority to execute and deliver this Agreement and to perform the transactions contemplated hereby.

(b) The execution, delivery, and performance by Seller of this Agreement and the consummation of the transaction contemplated hereby are within the power of Seller and have been duly authorized by all necessary actions on the part of Seller. The execution of this Agreement by Seller constitutes, or will at the Closing constitute, a legal, valid and binding obligation of Seller, enforceable against Seller in accordance with its terms, except as limited by bankruptcy, insolvency, or other laws of general application relating to or affecting the enforcement of creditors’ rights generally and general principles of equity.

(c) No consent, approval, authorization or order of, or registration or filing (other than any filing to be made with the U.S. Patent Office to record the Patent Assignment) with, or notice to, any court or governmental agency or body having jurisdiction or regulatory authority over Seller (or any of its properties) is required for (i) Seller’s execution and delivery of this Agreement (and each agreement executed and delivered by it in connection herewith) or (ii) the consummation by Seller of the transactions contemplated by this Agreement (and each

 

5


agreement executed and delivered by it in connection herewith) or, to the extent so required, such consent, approval, authorization, order, registration, filing or notice has been obtained, made or given (as applicable) and is still in full force and effect. Notwithstanding the foregoing, except with respect to Patents that are abandoned or expired as of the Effective Date, Seller has paid and, as of the Effective Date, is current on the payment of all maintenance fees, annuities, and the like, due and owing to any governmental bodies and other third parties in connection with the Transfer Assets, and Seller has obtained all necessary intellectual property assignments from inventors to Seller in connection with the Transfer Assets, except, in each case, as would not reasonably be expected to have a material adverse effect.

(d) Seller has good and marketable title to and, on the Closing Date, Seller will convey to Purchaser, all of the Transfer Assets, free and clear from any lien, security interest or other encumbrance.

(e) The execution, delivery and performance by Seller of this Agreement and the consummation of the transactions contemplated hereby will not conflict with, or result in a breach of or a constitute a default under, or result in the creation of any lien, security interest or other encumbrance upon the Transfer Assets under, any provision of (i) Seller’s certificate of incorporation or bylaws; (ii) any applicable law; or (iii) any contract to which Seller is a party or by which any Transfer Asset is bound.

(f) There is no judicial, governmental or administrative action, investigation, audit, claim, suit, arbitration, proceeding or other litigation to which Seller or any of its affiliates is a party, or to which the Transfer Assets are subject, that is pending or, to the Knowledge of Seller, threatened. No order, judgment, settlement agreement or stipulation has been issued or entered into that restricts in any respect the use, provision, transfer, assignment or licensing of the Transfer Assets.

(g) Except for the representations and warranties contained in this Section 8, neither Seller nor any other person or entity makes any other express or implied representation or warranty with respect to Seller, any of its affiliates or the transactions contemplated by this Agreement, and Seller disclaims any other representations or warranties, whether made by Seller, any of its affiliates, or any of their respective officers, directors, employees, agents or representatives. Except for the representations and warranties contained in this Section 8, Seller hereby disclaims all liability and responsibility for, or any use by Purchaser or its affiliates or representatives of, any representation, warranty, projection, forecast, statement or information made, communicated or furnished (orally or in writing) to Purchaser or its affiliates or representatives (including any opinion, information, projection or advice that may heretofore have been or may hereafter be made available to Purchaser or its affiliates or representatives, whether in any “data rooms,” “management presentations,” or “break out sessions,” in response to questions submitted by or on behalf of Purchaser or otherwise by any director, officer, employee, agent, or representative of Seller or any of its respective affiliates). The parties agree that any matter, condition or set of facts which is more specifically (rather than generally or by implication) covered in any of the representations and warranties of this Section 8 shall be solely governed by such more specific representation and warranty without reference to or inclusion within a more generalized representation and warranty that but for this sentence could be applicable to such matter, condition or set of facts.

 

6


9. Representations and Warranties of Purchaser. Purchaser represents and warrants to Seller, as follows:

(a) Purchaser (i) is a corporation duly organized, validly existing, and in good standing under the laws of its jurisdiction of incorporation and (ii) has all requisite corporate power and authority to execute and deliver this Agreement and to perform the transactions contemplated hereby.

(b) The execution, delivery, and performance by Purchaser of this Agreement and the consummation of the transaction contemplated hereby are within the power of Purchaser and have been duly authorized by all necessary actions on the part of Purchaser. The execution of this Agreement by Purchaser constitutes, or will at the Closing constitute, a legal, valid and binding obligation of Purchaser, enforceable against Purchaser in accordance with its terms, except as limited by bankruptcy, insolvency, or other laws of general application relating to or affecting the enforcement of creditors’ right generally and general principles of equity.

(c) No consent, approval, authorization or order of, or registration or filing with, or notice to, any court or governmental agency or body having jurisdiction or regulatory authority over Purchaser (or any of its properties) is required for (i) Purchaser’s execution and delivery of this Agreement (and each agreement executed and delivered by it in connection herewith) or (ii) the consummation by Purchaser of the transactions contemplated by this Agreement (and each agreement executed and delivered by it in connection herewith) or, to the extent so required, such consent, approval, authorization, order, registration, filing or notice has been obtained, made or given (as applicable) and is still in full force and effect.

(d) No person or entity acting on behalf of Purchaser or any of its affiliates or under the authority of any of them is or will be entitled to any “brokers” or “finders” fee or any other commission or similar fee, directly or indirectly, from Purchaser or any of its affiliates in connection with any of the transactions contemplated hereby.

(e) Notwithstanding anything contained in this Agreement to the contrary, Purchaser acknowledges and agrees that Seller is not making any representations or warranties whatsoever, express or implied, beyond those expressly given by Seller in Section 8, and Purchaser acknowledges and agrees that, except for such representations and warranties contained therein, the Transfer Assets of Seller are being transferred to Purchaser on a “where is” and, as to condition, “as is” basis. Any claims Purchaser may have for breach of representation or warranty shall be based solely on the representations and warranties of Seller set forth in Section 8. Purchaser further represents that none of Seller, its affiliates nor any other person or entity has made, and Purchaser has not relied upon, any representation or warranty, express or implied, as to the accuracy or completeness of any information regarding Seller, the Transfer Assets or the transactions contemplated by this Agreement not expressly set forth in Section 8 and Purchaser hereby expressly disclaims any reliance on any representations or warranties other than those expressly set forth in Section 8. Purchaser hereby acknowledges and agrees that none of Seller, any of its affiliates nor any other person or entity will have or be subject to any liability to Purchaser or any other person or entity resulting from the distribution to Purchaser or its representatives or Purchaser’s use of any such information, including any confidential memoranda distributed on behalf of Seller relating to the Transfer Assets or other publications, data room information or any

 

7


other document or information in any form provided to Purchaser or its representatives in connection with the sale of the Transfer Assets and the transactions contemplated hereby other than this Agreement including its exhibits and the documents delivered by Seller at the Closing pursuant to express requirements of this Agreement. Purchaser acknowledges that it (i) has conducted, to its satisfaction, its own independent investigation of the condition of the Transfer Assets and the business of Seller in making its determination to proceed with the transactions contemplated by this Agreement, Purchaser has relied on the results of its own independent investigation and, except with respect to those representations or warranties expressly set forth in Section 8, waives any right it may have against Seller with respect to any omission of any kind on the part of Seller of any potentially material information other than a failure to disclose information constituting material exceptions to the representations and warranties of set forth in Section 8, (ii) had adequate access to Seller’s books and records, contracts, agreements and documents, and employees, agents and representatives; and (iii) has had such opportunity to seek accounting, legal and other advice or information in connection with its entry into this Agreement and the other documents referred to herein relating to the consummation of the transactions contemplated hereby and thereby as it has seen fit.

10. Survival; Limitations of Liability. All representations and warranties contained in this Agreement shall survive the Closing and shall terminate on the earlier of (i) date that is forty-five (45) days following the Closing Date or (ii) the closing date of the Merger. IN NO EVENT WILL SELLER BE LIABLE FOR ANY INDIRECT, SPECIAL, INCIDENTAL, EXEMPLARY, PUNITIVE OR CONSEQUENTIAL DAMAGES IN CONNECTION WITH OR RELATED TO THIS AGREEMENT (INCLUDING LOSS OF PROFITS, USE, DATA, OR OTHER ECONOMIC ADVANTAGE), HOWSOEVER ARISING, EITHER OUT OF BREACH OF THIS AGREEMENT (INCLUDING BREACH OF EXPRESS OR IMPLIED WARRANTY), NEGLIGENCE, STRICT LIABILITY, TORT OR ANY OTHER THEORY, EVEN IF THE OTHER PARTY HAS BEEN PREVIOUSLY ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. EXCEPT FOR ANY CLAIMS BASED UPON OR ARISING FROM (A) ANY ACTION SEEKING EQUITABLE REMEDY OR SPECIFIC PERFORMANCE BROUGHT AGAINST SELLER FOR FAILURE TO DELIVER THE TRANSFER ASSETS AS CONTEMPLATED BY SECTION 1, OR (B) SELLER’S ACTUAL FRAUD (AS DEFINED BELOW), SELLER’S LIABILITY FOR DAMAGES ARISING UNDER THIS AGREEMENT SHALL BE LIMITED TO THE VALUE OF THE PURCHASE AMOUNT. Recovery of the Purchase Amount by Purchaser shall be Seller’s sole liability and Purchaser’s sole remedy for the matters described in this Section 10, and Purchaser shall not be entitled to any other remedy or indemnification rights or claims of any nature whatsoever against Seller, its affiliates or any other person or entity in respect thereof or otherwise in connection with this Agreement. For purposes of this Agreement, “Actual Fraud” means an inaccurate representation or warranty contained in this Agreement if, at the time such representation or warranty was made, Seller had actual knowledge of the inaccuracy of such representation or warranty and failed to notify Purchaser in writing of, or otherwise correct, the same.

11. Expenses. Purchaser and Seller shall each bear their own expenses incurred in connection with the transactions contemplated by this Agreement.

 

8


12. Transfer Taxes. Purchaser shall pay all sales, use, excise, stamp, documentary, filing, recording, transfer or similar fees or taxes or governmental charges, as levied by any taxing authority or governmental agency in connection with the sale and transfer of Transfer Assets contemplated by this Agreement. Prior to the Closing Date, (a) Purchaser shall deliver to Seller evidence that these transactions are exempt from sales tax, or (b) Purchaser shall remit to Seller any sales tax due as a result of these transactions. Seller hereby agrees to file all necessary documents with respect to such amounts in a timely manner.

13. Notices. Any notice or other communication provided for herein or given hereunder to a party hereto shall be in writing, and shall be deemed given when personally delivered to a party set forth below or when sent by telecopy providing a transmission confirmation (provided that such notice is immediately sent by a recognized overnight delivery service), or three (3) days after mailed by first class mail, registered, or certified, return receipt requested, postage prepaid, or when delivered by a nationally-recognized overnight delivery service, with proof of delivery, delivery charges prepaid, in any case addressed as follows.

To Seller:

Aerpio Pharmaceuticals, Inc.

c/o Regina Marek

10663 Loveland-Madeira Road #168

Loveland, Ohio 45140

with a copy to:

Goodwin Procter LLP

100 Northern Avenue

Boston, MA 02210

Attention: Kingsley Taft

To Purchaser:

EyePoint Pharmaceuticals, Inc.

480 Pleasant Street, Suite A210

Watertown, MA 02472

Attention: Chief Legal Officer

14. Miscellaneous.

(a) Entire Agreement. This Agreement, together with the schedules and exhibits attached hereto, constitutes the entire agreement of the parties hereto regarding the purchase and sale of the Transfer Assets, and all prior agreements, understandings, representations and statements regarding such subject matter, oral or written, are superseded hereby.

(b) Captions. Section captions used in this Agreement are for convenience only, and do not affect the construction of this Agreement.

(c) Counterpart Execution. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original and all of which shall together constitute one and the same instrument. Delivery of an executed counterpart of a signature page to this Agreement by facsimile transmission or by e-mail in .PDF or similar electronic format shall be effective as delivery of a manually executed counterpart thereof and shall be deemed an original signature for all purposes.

 

9


(d) Severability. If any provision of this Agreement shall for any reason be held to be invalid or unenforceable, such invalidity or unenforceability shall not affect any other provision of this Agreement, but this Agreement shall be construed as if such invalid or unenforceable provision had never been contained in this Agreement.

(e) Amendments and Waivers. No amendment of any provision of this Agreement shall be valid unless the same shall be in writing and signed by Purchaser and Seller, and no waiver of any provision of this Agreement shall be valid unless the same shall be in writing and signed by the party against which such waiver is to be enforced. No waiver by any party hereto of any default, misrepresentation, condition precedent or breach of warranty or covenant hereunder, whether intentional or not, shall be deemed to extend to any other default, misrepresentation, condition precedent or breach of warranty or covenant hereunder or affect in any way any rights arising by virtue of any prior or subsequent such occurrence.

(f) Governing Law. This Agreement shall be governed by and interpreted in accordance with the internal laws of the Commonwealth of Massachusetts (without reference to conflicts of law principles).

(g) Waiver of Trial by Jury. SELLER AND PURCHASER HEREBY EXPRESSLY WAIVE ANY RIGHT TO TRIAL BY JURY OF ANY CLAIM, DEMAND, ACTION, CAUSE OF ACTION, OR PROCEEDING ARISING UNDER OR WITH RESPECT TO THIS AGREEMENT, OR IN ANY WAY CONNECTED WITH, OR RELATED TO, OR INCIDENTAL TO, THE DEALINGS OF THE PARTIES HERETO WITH RESPECT TO THIS AGREEMENT OR THE TRANSACTIONS RELATED HERETO OR THERETO, IN EACH CASE WHETHER NOW EXISTING OR HEREAFTER ARISING, AND IRRESPECTIVE OF WHETHER SOUNDING IN CONTRACT, TORT, OR OTHERWISE. SELLER AND PURCHASER HEREBY AGREE THAT ANY SUCH CLAIM, DEMAND, ACTION, CAUSE OF ACTION, OR PROCEEDING SHALL BE DECIDED BY A COURT TRIAL WITHOUT A JURY AND THAT ANY PARTY HERETO MAY FILE AN ORIGINAL COUNTERPART OR A COPY OF THIS SECTION WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF THE OTHER PARTY OR PARTIES HERETO TO WAIVER OF ITS OR THEIR RIGHT TO TRIAL BY JURY.

(h) Submission to Jurisdiction; Selection of Forum. EACH PARTY HERETO (A) AGREES THAT IT SHALL BRING ANY ACTION OR PROCEEDING IN RESPECT OF ANY CLAIM ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE TRANSACTIONS CONTAINED IN OR CONTEMPLATED BY THIS AGREEMENT, WHETHER IN TORT OR CONTRACT OR AT LAW OR IN EQUITY, EXCLUSIVELY IN (I) THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MASSACHUSETTS OR IN THE EVENT THAT SUCH COURT LACKS SUBJECT MATTER JURISDICTION OVER THE ACTION OR PROCEEDING, (II) IN AN APPROPRIATE STATE COURT LOCATED IN THE COUNTY OF SUFFOLK, MASSACHUSETTS (THE “CHOSEN COURT”), (B) IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE CHOSEN COURT, (C) WAIVES, TO THE EXTENT PERMITTED BY APPLICABLE LAW,

 

10


ANY OBJECTION TO LAYING VENUE IN ANY SUCH ACTION OR PROCEEDING IN THE CHOSEN COURT, (D) WAIVES ANY ARGUMENT THAT THE CHOSEN COURT IS AN INCONVENIENT FORUM OR DOES NOT HAVE JURISDICTION OVER ANY PARTY THERETO, AND (E) AGREES THAT SERVICE OF PROCESS UPON ANY PARTY IN ANY SUCH ACTION OR PROCEEDING SHALL BE EFFECTIVE IF NOTICE IS GIVEN IN ACCORDANCE WITH SECTION 13 OF THIS AGREEMENT.

(i) Construction. The parties hereto have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any of the provisions of this Agreement. Any reference to any federal, state, local, or foreign statute or law shall be deemed also to refer to all rules and regulations promulgated thereunder, unless the context requires otherwise. The word “including” shall mean “including without limitation.”

(j) No Third-Party Beneficiaries. This Agreement shall not confer any rights or remedies upon any person or entity other than the parties hereto and their respective successors and permitted assigns.

(k) Successor and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties named herein and their respective successors and permitted assigns. Neither party may assign its rights or obligations hereunder without obtaining the prior written consent of the other party; provided, however, that each party shall be entitled, without the prior written consent of the other party, to assign its rights and obligations under this Agreement to an affiliate or to its successor in connection with the sale of all or substantially all of its business or assets related to this Agreement, whether by way of merger, consolidation, sale of stock, sale of assets, operation of law or otherwise, subject in each case to the assignee agreeing in writing to be bound by the terms and conditions of this Agreement. Any attempted assignment, delegation or transfer by a party in violation hereof shall be null and void. Subject to the foregoing, this Agreement shall be binding on the parties and their successors and permitted assigns.

(l) Confidentiality.

i. Purchaser agrees that it will treat in complete confidence all documents, materials and other information, made available by Seller to the Purchaser in connection with the transaction contemplated herein or the negotiation of this Agreement (the “Confidential Information”) and shall use such Confidential Information solely to evaluate the proposed purchase and sale of the Transfer Assets (the “Purpose”); provided, however, that after Closing Date Purchaser may use or disclose any Confidential Information included in the Transfer Assets or otherwise necessary to exercise its rights or obligations under this Agreement. Purchaser shall not, directly or indirectly, disclose, publish, divulge, furnish or make accessible to anyone all or any portion of the Confidential Information, other than (A) to Purchaser’s employees and consultants who are required to have access to such Confidential Information in connection with the Purpose, (B) to Purchaser’s professional advisers (e.g., lawyers and accountants), provided that any and all such employees and consultants are bound by written agreements or, in the case of professional advisers, ethical duties, respecting the Confidential Information in the manner set forth in this Agreement and (C) retention of a copy of the Materials that constitute electronic

 

11


records by Seller for ordinary archival and recordkeeping purposes. If the transactions contemplated hereby are not consummated, the Purchaser will promptly return to the Seller all Confidential Information. In addition to the restrictions set forth in this Section 14(l), but subject to the terms of Section 14(m), each party agrees that it shall not, at any point prior to or after the Closing Date, without the prior written consent of the other party, disclose the existence or terms or conditions of this Agreement.

ii. Confidential Information shall not include any information that (A) at the time of disclosure is available to the public, (B) after the date of disclosure becomes generally available to the public, except through a breach of this Section 14(l), (C) is independently developed by the employees or agents of the Purchaser without use of or reference to the Confidential Information, (D) that is received from a third party without restriction and without breach of any agreement between such third party and the Seller.

iii. In the event that the Purchaser is required by law to make any disclosure of any of the Confidential Information, by subpoena, judicial or administrative order or otherwise, the Purchaser shall first give written notice of such requirement to the Seller, and shall permit the Seller to intervene in any relevant proceedings to protect its interests in the Confidential Information, and provide full cooperation and assistance to the Seller in seeking to obtain such protection.

iv. Each party acknowledges that a breach by it of any of the terms of this Agreement would cause irreparable harm to the other party for which the other party could not be adequately compensated by money damages. Accordingly, each party agrees that, in addition to all other remedies available to the other party in an action at law, in the event of any breach or threatened breach by a party of the terms of this Section 14(l), the other party shall, without the necessity of proving actual damages or posting any bond or other security, be entitled to seek temporary and permanent injunctive relief, including, but not limited to, specific performance of the terms of this Section 14(l).

(m) Public Announcements. No party shall issue or make any public announcement, press release or other public disclosure regarding this Agreement or its subject matter without the prior written approval of the other party, except for any such disclosure that is, in the opinion of the disclosing party’s counsel, required by applicable law (including securities regulations) or the rules of a stock exchange on which the securities of the disclosing party are listed. Notwithstanding anything to the contrary contained in this Agreement, following the Closing, (i) Purchaser and its licensees, sublicensees and other collaborators shall be permitted, without the prior approval of or prior notice to Seller, to disclose for any purpose, and to make publications and public presentations regarding, progress and results with respect to the development and commercialization of the Transfer Assets; and (ii) Purchaser shall be permitted, without the prior approval of or prior notice to Seller, to disclose the existence and terms of this Agreement, other than the amount of the Purchase Price, to actual and potential investors, licensees, sublicensees, collaborators and acquirers on a reasonable need-to-know basis under circumstances that reasonably ensure the confidentiality thereof. If a party is, in the opinion of its counsel, required by applicable law (including securities regulations) or the rules of a stock exchange on which its securities are listed to make a public disclosure regarding this Agreement or its subject matter, such party shall, if practicable under the circumstances, submit the proposed

 

12


disclosure in writing to the other party and provide the other party a reasonable opportunity to comment thereon. The contents of any public announcement, press release or other public disclosure that has been made in compliance with this Section 14(l) may then be re-released by any party without a requirement for advance notice or re-approval.

(n) Termination. Each of Seller and Purchaser shall have the right to terminate its obligations to complete the Closing and the transactions contemplated in connection therewith in the event that the other party materially breaches this Agreement and such breach is not cured within thirty (30) days after such other party receives notice from the first party of such material breach. For the avoidance of doubt, the Joint Escrow Instructions provide that the Purchaser and Seller shall instruct the Escrow Agent to release the Purchase Amount to Purchaser following any such termination.

[Signature Page Follows]

 

13


IN WITNESS WHEREOF, Purchaser and Seller have caused this Agreement to be executed as of the Effective Date.

 

AERPIO PHARMACEUTICALS, INC.
By:  

/s/ Joseph Gardner

Name: Joseph Gardner
Title: President
EYEPOINT PHARMACEUTICALS, INC.
By:  

/s/ George Elston

Name: George Elston

Title: Chief Financial Officer and

Head of Corporate Development

Signature page to Asset Purchase Agreement


EXHIBIT A

BILL OF SALE

[Omitted pursuant to Item 601(a)(5) of Regulation S-K]

EXHIBIT B

TRANSFER ASSETS

Patents and Patent Applications

ATTACHMENT A

 

Country

   Application No.    Filing
Date
   Patent No.    Patent
Date
  

Title

United States    60/816,730    06/27/2006          HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United States    60/816,731    06/27/2006          HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United States    60/816,825    06/27/2006          HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United States    11/823,086    06/26/2007    7,622,593    11/24/2009    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United States    11/821,846    06/26/2007    7,795,444    09/14/2010    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United States    11/821,868    06/26/2007    7,589,212    09/15/2009    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United States    12/624,072    11/23/2009    8,258,311    09/04/2012    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United States    13/309,452    12/01/2011    8,338,615    12/25/2012    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United States    13/691,757    12/01/2012    8,946,232    02/03/2015    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United States    13/936,450    07/08/2013    8,895,563    11/25/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE


United States    13/309,445    12/01/2011    8,329,916    12/11/2012    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United States    14/569,106    12/12/2014    9,126,958    09/08/2015    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United States    14/252,140    04/14/2014    9,284,285    03/15/2016    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United States    15/016,599    02/05/2016    9,795,594    10/24/2017    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United States    15/705,639    09/15/2017    10,463,650    11/05/2019    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United States    16/577,808    09/20/2019          HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United States    17/096,548    11/12/2020          HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United States    12/558,169    09/11/2009          HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United States    12/850,026    08/04/2010    8,106,078    01/31/2012    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United States    12/467,430    05/18/2009    8,188,125    05/29/2012    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United States    13/626,590    09/25/2012          HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United States    13/626,614    09/25/2012    8,846,685    09/30/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United States    14/938,526    11/11/2015    RE46,592    10/31/2017    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
WO    PCT/
US2007/014822
   06/27/2007          HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE

 

2


WO    PCT/
US2007/014823
   06/27/2007          HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
WO    PCT/
US2007/014824
   06/27/2007          HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Europe    7809907.4    06/27/2007    2041102    11/12/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Europe    12196174.2    06/27/2007    2592072    09/20/2017    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Europe    17191765.1    06/27/2007    3323815    10/07/2020    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Europe    07809908.2    06/27/2007    2038265    03/18/2015    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Europe    12196179.1    06/27/2007    2592073    08/30/2017    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Europe    17187910.9    06/27/2007          HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Europe    07809909.0    06/27/2007    2041129    09/03/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Europe    14166121.5    06/27/2007    2803663    11/29/2017    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Europe    17182516.9    06/27/2007          HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Germany    07809909.0    06/27/2007    2041129    09/03/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Germany    12196174.2    06/27/2007    602007052457.1    09/20/2017    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE

 

3


Germany    602007052232.3    06/27/2007    2592073    08/30/2017    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Germany    602007053259.0    06/27/2007    2803663    11/29/2017    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Germany    17191765.1    06/27/2007    3323815    10/07/2020    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Germany    07809907.4    06/27/2007    2041102    11/12/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Germany    07809908.2    06/27/2007    2038265    03/18/2015    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
France    07809909.0    06/27/2007    2041129    09/03/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
France    12196174.2    06/27/2007    2592072    09/20/2017    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
France    12196179.1    06/27/2007    2592073    08/30/2017    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
France    14166121.5    06/27/2007    2803663    11/29/2017    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
France    17191765.1    06/27/2007    3323815    10/07/2020    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
France    07809907.4    06/27/2007    2041102    11/12/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
France    7809908.2    06/27/2007    2038265    03/18/2015    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United Kingdom    07809909.0    06/27/2007    2041129    09/03/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE

 

4


United Kingdom    12196179.1    06/27/2007    2592073    08/30/2017    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United Kingdom    12196174.2    06/27/2007    2592072    09/20/2017    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United Kingdom    14166121.5    06/27/2007    2803663    11/29/2017    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United Kingdom    17191765.1    06/27/2007    3323815    10/07/2020    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United Kingdom    07809907.4    06/27/2007    2041102    11/12/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United Kingdom    07809908.2    06/27/2007    2038265    03/18/2015    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Austria    07809909.0    06/27/2007    2041129    09/03/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Austria    07809907.4    06/27/2007    2041102    11/12/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Austria    07809908.2    06/27/2007    2038265    03/18/2015    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Austria    12196174.2    06/27/2007    2592072    09/20/2017    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Austria    14166121.5    06/27/2007    2803663    11/29/2007    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Austria    17191765.1    06/27/2007    3323815    10/07/2020    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Belgium    07809909.0    06/27/2007    2041129    09/03/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Belgium    07809907.4    06/27/2007    2041102    11/12/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE

 

5


Belgium    07809908.2    06/27/2007    2038265    03/18/2015    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Belgium    07809909.0    06/27/2007    2592072    09/20/2017    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Belgium    07809907.4    06/27/2007    2803663    11/29/2017    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Belgium    17191765.1    06/27/2007    3323815    10/07/2020    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Bulgaria    07809909.0    06/27/2007    2041129    09/03/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Bulgaria    7809907.4    06/27/2007    2041102    11/12/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Bulgaria    07809908.2    06/27/2007    2038265    03/18/2015    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Lithuania    07809909.0    06/27/2007    2041129    09/03/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Lithuania    07809907.4    06/27/2007    2041102    11/12/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Lithuania    07809908.2    06/27/2007    2038265    03/18/2015    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Latvia    07809909.0    06/27/2007    2041129    09/03/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Latvia    07809907.4    06/27/2007    2041102    11/12/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Latvia    07809908.2    06/27/2007    2038265    03/18/2015    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE

 

6


Switzerland    7809909    06/27/2007    2041129    09/03/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Switzerland    7809907.4    06/27/2007    2041102    11/12/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Switzerland    07809908.2    06/27/2007    2038265    03/18/2015    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Switzerland    12196174.2    06/27/2007    2592072    09/20/2017    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Switzerland    14166121.5    06/27/2007    2803663    11/20/2017    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Switzerland    17191765.1    06/27/2007    3323815    10/07/2020    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Cyprus    07809909.0    06/27/2007    2041129    09/03/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Cyprus    07809907.4    06/27/2007    2041102    11/12/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Cyprus    07809908.2    06/27/2007    2038265    03/18/2015    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Czech Republic    07809909.0    06/27/2007    2041129    09/03/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Czech Republic    07809907.4    06/27/2007    2041102    11/12/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Czech Republic    07809908.2    06/27/2007    2038265    03/18/2015    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Czech Republic    12196174.2    06/27/2007    2592072    09/20/2017    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Denmark    07809909.0    06/27/2007    2041129    09/03/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE

 

7


Denmark    07809907.4    06/27/2007    2041102    11/12/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Denmark    07809908.2    06/27/2007    2038265    03/18/2015    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Denmark    12196174.2    06/27/2007    2592072    09/20/2017    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Denmark    14166121.5    06/27/2007    2803663    11/29/2017    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Denmark    17191765.1    06/27/2007    3323815    10/07/2020    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Estonia    07809909.0    06/27/2007    2041129    09/03/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Estonia    07809907.4    06/27/2007    2041102    11/12/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Estonia    07809908.2    06/27/2007    2038265    03/18/2015    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Spain    07809909.0    06/27/2007    2041129    09/03/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Spain    07809907.4    06/27/2007    2041102    11/12/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Spain    07809908.2    06/27/2007    2038265    03/18/2015    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Spain    12196174.2    06/27/2007    2592072    09/20/2017    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Spain    14166121.5    06/27/2007    2803663    11/29/2017    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE

 

8


Spain    17191765.1    06/27/2007    3323815    10/07/2020    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Finland    07809909.0    06/27/2007    2041129    09/03/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Finland    07809907.4    06/27/2007    2041102    11/12/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Finland    07809908.2    06/27/2007    2038265    03/18/2015    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Finland    12196174.2    06/27/2007    2592072    09/20/2017    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Finland    14166121.5    06/27/2007    2803663    11/29/2017    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Finland    17191765.1    06/27/2007    3323815    10/07/2020    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Greece    07809909.0    06/27/2007    2041129    09/03/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Greece    07809907.4    06/27/2007    2041102    11/12/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Greece    07809908.2    06/27/2007    2038265    03/18/2015    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Hungary    07809909.0    06/27/2007    2041129    09/03/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Hungary    07809907.4    06/27/2007    2041102    11/12/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Hungary    07809908.2    06/27/2007    2038265    03/18/2015    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Iceland    07809909.0    06/27/2007    2041129    09/03/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE

 

9


Iceland    07809907.4    06/27/2007    2041102    11/12/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Iceland    07809908.2    06/27/2007    2038265    03/18/2015    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Ireland    07809909.0    06/27/2007    2041129    09/03/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Ireland    07809907.4    06/27/2007    2041102    11/12/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Ireland    07809908.2    06/27/2007    2038265    03/18/2015    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Ireland    12196174.2    06/27/2007    2592072    09/20/2017    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Ireland    12196179.1    06/27/2007    2592073    08/30/2017    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Ireland    14166121.5    06/27/2007    2803663    11/29/2017    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Ireland    17191765.1    06/27/2007    3323815    10/07/2020    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Italy    07809909.0    06/27/2007    2041129    09/03/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Italy    07809907.4    06/27/2007    2041102    11/12/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Italy    07809908.2    06/27/2007    2038265    03/18/2015    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Italy    12196174.2    06/27/2007    2592072    09/20/2017    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE

 

10


Italy    12196179.1    06/27/2007    2592073    08/30/2017    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Italy    14166121.5    06/27/2007    2803663    11/29/2017    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Italy    17191765.1    06/27/2007    3323815    10/07/2020    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Luxembourg    07809909.0    06/27/2007    2041129    09/03/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Luxembourg    7809907.4    06/27/2007    2041102    11/12/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Luxembourg    07809908.2    06/27/2007    2038265    03/18/2015    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Malta    07809909.0    06/27/2007    2041129    09/03/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Malta    07809907.4    06/27/2007    2041102    11/12/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Malta    07809908.2    06/27/2007    2038265    03/18/2015    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Monaco    07809909.0    06/27/2007    2041129    09/03/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Monaco    07809907.4    06/27/2007    2041102    11/12/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Monaco    07809908.2    06/27/2007    2038265    03/18/2015    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Netherlands    07809909.0    06/27/2007    2041129    09/03/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Netherlands    07809907.4    06/27/2007    2041102    11/12/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE

 

11


Netherlands    07809908.2    06/27/2007    2038265    03/18/2015    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Netherlands    12196174.2    06/27/2007    2592072    09/20/2017    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Netherlands    14166121.5    06/27/2007    2803663    11/29/2017    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Netherlands    17191765.1    06/27/2007    3323815    10/07/2020    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Poland    07809909.0    06/27/2007    2041129    09/03/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Poland    07809907.4    06/27/2007    2041102    11/12/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Poland    07809908.2    06/27/2007    2038265    03/18/2015    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Poland    12196174.2    06/27/2007    2592072    09/20/2017    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Poland    14166121.5    06/27/2007    2803663    11/29/2017    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Poland    17191765.1    06/27/2007    3323815    10/07/2020    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Portugal    07809909.0    06/27/2007    2041129    09/03/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Portugal    07809907.4    06/27/2007    2041102    11/12/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Portugal    07809908.2    06/27/2007    2038265    03/18/2015    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE

 

12


Portugal    12196174.2    06/27/2007    2592072    09/20/2017    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Portugal    14166121.5    06/27/2007    2803663    11/29/2017    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Portugal    17191765.1    06/27/2007    3323815    10/07/2020    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Romania    07809909.0    06/27/2007    2041129    09/03/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Romania    07809907.4    06/27/2007    2041102    11/12/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Romania    07809908.2    06/27/2007    2038265    03/18/2015    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Sweden    07809909.0    06/27/2007    2041129    09/03/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Sweden    07809907.4    06/27/2007    2041102    11/12/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Sweden    07809908.2    06/27/2007    2038265    03/18/2015    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Sweden    12196174.2    06/27/2007    2592072    09/20/2017    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Sweden    14166121.5    06/27/2007    2803663    11/29/2017    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Sweden    17191765.1    06/27/2007    3323815    10/07/2020    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Slovenia    07809909.0    06/27/2007    2041129    09/03/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Slovenia    07809907.4    06/27/2007    2041102    11/12/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE

 

13


Slovenia    07809908.2    06/27/2007    2038265    03/18/2015    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Slovakia    07809909.0    06/27/2007    2041129    09/03/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Slovakia    07809907.4    06/27/2007    2041102    11/12/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Slovakia    07809908.2    06/27/2007    2038265    03/18/2015    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Turkey    07809909.0    06/27/2007    TR 2014
12834 T4
   09/03/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Turkey    07809907.4    06/27/2007    2041102    11/12/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Turkey    07809908.2    06/27/2007    TR 2015
04305 T4
   03/18/2015    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Turkey    12196174.2    06/27/2007    2592072    09/20/2017    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Turkey    14166121.5    06/27/2007    2803663    11/29/2017    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Australia    2007265453    06/27/2007    2007265453    05/03/2012    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Australia    2007265454    06/27/2007    2007265454    02/09/2012    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Australia    2007265455    06/27/2007    2007265455    02/23/2012    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Australia    2012200253    06/27/2007    2012200253    10/18/2012    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Brazil    PI
0713570-0
   06/27/2007          HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE

 

14


Brazil    PI 0713357-0    06/27/2007          HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Brazil    PI 0713349-9    06/27/2007          HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Canada    2,657,096    06/27/2007    2,657,096    01/21/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Canada    2,657,107    06/27/2007    2,657,107    01/07/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Canada    2,656,915    06/27/2007    2,656,915    08/07/2012    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
China    200780030939.0    06/27/2007    ZL200780030939.0    08/08/2012    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
China    200780030984.6    06/27/2007    ZL200780030984.6    10/30/2013    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
China    200780031040.0    06/27/2007    ZL200780031040.0    05/30/2012    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Colombia    9007333    06/27/2007    3672       HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Colombia    9007334    06/27/2007    3673       HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Colombia    9007327    06/27/2007    2408    10/29/2012    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Hong Kong    09108319.8    06/27/2007    1129386    01/22/2016    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Hong Kong    13112445.1    06/27/2007          HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE

 

15


Hong Kong    09108320.5    06/27/2007    1129387B    10/02/2015    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Hong Kong    13112446    06/27/2007          HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Hong Kong    09108321.4    06/27/2007          HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Hong Kong    15104703.3    06/27/2007          HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Israel    196128    06/27/2007    196128    11/30/2013    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Israel    196129    06/27/2007    196129    06/25/2013    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Israel    196130    06/27/2007    196130    07/31/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
India    515/DELNP/2009    06/27/2007    280469    02/22/2017    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
India    513/DELNP/2009    06/27/2007    289597    11/15/2017    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
India    512/DELNP/2009    06/27/2007          HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Indonesia    W00200804210    06/27/2007    IDP000047234    08/09/2017    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Indonesia    W-00200804213    06/27/2007    IDP000045140    03/14/2017    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Indonesia    W-00200804212    06/27/2007    IDP000040030    12/21/2015    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE

 

16


Japan    2009-518226    06/27/2007    5232778    03/29/2013    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Japan    2013-062411    06/27/2007    5860427    12/25/2015    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Japan    2009-518227    06/27/2007    5261383    05/02/2013    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Japan    2013-029649    06/27/2007          HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Japan    2015-178320    06/27/2007          HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Japan    2015-178321    06/27/2007          HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Japan    2017-213854    06/27/2007          HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Japan    2017-213855    06/27/2007          HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Japan    2009-518228    06/27/2007    5201740    02/22/2013    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Korea    10-2009-7001678    06/27/2007    1155365    06/05/2012    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Korea    10-2009-7001694    06/27/2007    1179087    08/28/2012    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Korea    2009-7001692    06/27/2007    1157844    06/13/2012    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Mexico    MX/a/2009/000288    06/27/2007    321351    06/24/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Mexico    MX/a/2009/000289    06/27/2007    303155    09/06/2012    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE

 

17


Mexico    MX/a/
2009/000290
   06/27/2007    279959    10/14/2010    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
New Zealand    574407    06/27/2007    574407    06/05/2012    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
New Zealand    574406    06/27/2007    574406    05/07/2012    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
New Zealand    574405    06/27/2007    574405    05/07/2012    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Philippines    1-2009-500031    06/27/2007    1-2009-500031    01/30/2012    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Philippines    1-2009-500032    06/27/2007    1-2009-500032    05/07/2014    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Philippines    1-2009-500033    06/27/2007    1-2009-500033    07/31/2013    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Russian Federation    2009102516    06/27/2007    2447065    12/10/2011    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Russian Federation    2009102538    06/27/2007    2435763    12/10/2011    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Russian Federation    2009102537    06/27/2007    2430101    09/27/2011    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Singapore    200809619-0    06/27/2007    149161    01/31/2012    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Singapore    200809621-6    06/27/2007    148804    07/29/2011    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Singapore    200809622-4    06/27/2007    148805    07/29/2011    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE

 

18


South Africa    2009/00559    06/27/2007    2009/00559    06/30/2010    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
South Africa    2009/00492    06/27/2007    2009/00492    06/30/2010    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
South Africa    2009/00558    06/27/2007    2009/00558    04/24/2012    HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United States    61/144,022    01/12/2009          METHODS FOR TREATING VASCULAR LEAK SYNDROME
United States    61/184,986    06/08/2009          METHODS FOR TREATING VASCULAR LEAK SYNDROME
United States    14/075,809    11/08/2013          METHODS FOR TREATING VASCULAR LEAK SYNDROME
United States    15/443,353    02/27/2017          METHODS FOR TREATING VASCULAR LEAK SYNDROME
United States    16/719,317    12/18/2019          METHODS FOR TREATING VASCULAR LEAK SYNDROME
United States    15/930,583    05/13/2020          METHODS FOR TREATING VASCULAR LEAK SYNDROME
United States    13/968,269    08/15/2013          METHODS FOR TREATING VASCULAR LEAK SYNDROME
United States    13/724,396    12/21/2012    9,096,555    08/04/2015    METHODS FOR TREATING VASCULAR LEAK SYNDROME
United States    12/677,512    03/22/2010          METHODS FOR TREATING VASCULAR LEAK SYNDROME
WO    PCT/US2010/020817    01/12/2010          METHODS FOR TREATING VASCULAR LEAK SYNDROME
Europe    10729682.4    01/12/2010    2385763    11/16/2011    METHODS FOR TREATING VASCULAR LEAK SYNDROME
Germany    10729682.4    01/12/2010    2385763    11/16/2011    METHODS FOR TREATING VASCULAR LEAK SYNDROME
France    10729682.4    01/12/2010    2385763    11/16/2011    METHODS FOR TREATING VASCULAR LEAK SYNDROME
United Kingdom    10729682.4    01/12/2010    2385763    11/16/2011    METHODS FOR TREATING VASCULAR LEAK SYNDROME

 

19


Austria    10729682.4    01/12/2010    2385763    04/18/2018    METHODS FOR TREATING VASCULAR LEAK SYNDROME
Belgium    10729682.4    01/12/2010    2385763    04/18/2018    METHODS FOR TREATING VASCULAR LEAK SYNDROME
Switzerland    10729682.4    01/12/2010    2385763    04/18/2018    METHODS FOR TREATING VASCULAR LEAK SYNDROME
Denmark    10729682.4    01/12/2010    2385763    04/18/2018    METHODS FOR TREATING VASCULAR LEAK SYNDROME
Spain    10729682.4    01/12/2010    2385763    04/18/2018    METHODS FOR TREATING VASCULAR LEAK SYNDROME
Finland    10729682.4    01/12/2010    2385763    04/18/2018    METHODS FOR TREATING VASCULAR LEAK SYNDROME
Ireland    10729682.4    01/12/2010    2385763    s04/18/2018    METHODS FOR TREATING VASCULAR LEAK SYNDROME
Italy    10729682.4    01/12/2010    2385763    04/18/2018    METHODS FOR TREATING VASCULAR LEAK SYNDROME
Netherlands    10729682.4    01/12/2010    2385763    04/18/2018    METHODS FOR TREATING VASCULAR LEAK SYNDROME
Norway    10729682.4    01/12/2010    2385763    04/18/2018    METHODS FOR TREATING VASCULAR LEAK SYNDROME
Poland    10729682.4    01/12/2010    2385763    04/18/2018    METHODS FOR TREATING VASCULAR LEAK SYNDROME
Portugal    10729682.4    01/12/2010    2385763    04/18/2018    METHODS FOR TREATING VASCULAR LEAK SYNDROME
Sweden    10729682.4    01/12/2010    2385763    04/18/2018    METHODS FOR TREATING VASCULAR LEAK SYNDROME
Turkey    10729682.4    01/12/2010    2385763    04/18/2018    METHODS FOR TREATING VASCULAR LEAK SYNDROME
Australia    2010203352    01/12/2010    2010203352    11/06/2014    METHODS FOR TREATING VASCULAR LEAK SYNDROME
Australia    2014202211    01/12/2010    2014202211    09/15/2016    METHODS FOR TREATING VASCULAR LEAK SYNDROME
Australia    2016203254    01/12/2010    2016203254    01/03/2019    METHODS FOR TREATING VASCULAR LEAK SYNDROME

 

20


Brazil    PI 1006898-8    01/12/2010          METHODS FOR TREATING VASCULAR LEAK SYNDROME
Canada    2,748,814    01/12/2010    2,748,814    02/25/2014    METHODS FOR TREATING VASCULAR LEAK SYNDROME
Canada    2,838,846    01/12/2010    2,838,846    01/19/2018    METHODS FOR TREATING VASCULAR LEAK SYNDROME
China    201080011867.7    01/12/2010          METHODS FOR TREATING VASCULAR LEAK SYNDROME
China    201810637424.7    01/12/2010          METHODS FOR TREATING VASCULAR LEAK SYNDROME
China    201910044287.0    01/12/2010          METHODS FOR TREATING VASCULAR LEAK SYNDROME
Hong Kong    12104707.2    01/12/2010          METHODS FOR TREATING VASCULAR LEAK SYNDROME
Indonesia    W00201102787    01/12/2010          METHODS FOR TREATING VASCULAR LEAK SYNDROME
Indonesia    P00201900995    01/12/2010          METHODS FOR TREATING VASCULAR LEAK SYNDROME
Israel    214047    01/12/2010    214047    02/01/2017    METHODS FOR TREATING VASCULAR LEAK SYNDROME
Israel    248340    01/12/2010    248340    12/21/2018    METHODS FOR TREATING VASCULAR LEAK SYNDROME
Israel    261374    01/12/2010          METHODS FOR TREATING VASCULAR LEAK SYNDROME
India    4961/DELNP/2011    01/12/2010          METHODS FOR TREATING VASCULAR LEAK SYNDROME
Japan    2011-545536    01/12/2010    5558489    06/13/2014    METHODS FOR TREATING VASCULAR LEAK SYNDROME
Japan    2014-116250    01/12/2010    5957035    06/24/2016    METHODS FOR TREATING VASCULAR LEAK SYNDROME
Korea    10-2011-7018768    01/12/2010    1495950    02/16/2015    METHODS FOR TREATING VASCULAR LEAK SYNDROME
Malaysia    PI 2011003558    01/12/2010    MY-158804-A    11/15/2016    METHODS FOR TREATING VASCULAR LEAK SYNDROME

 

21


Mexico    MX/a/2011/007419    01/12/2010    346984    04/07/2017    METHODS FOR TREATING VASCULAR LEAK SYNDROME
New Zealand    594535    01/12/2010    594535    01/07/2014    METHODS FOR TREATING VASCULAR LEAK SYNDROME
Philippines    1-2011-501369    01/12/2010          METHODS FOR TREATING VASCULAR LEAK SYNDROME
Russian Federation    2011133833    01/12/2010    2539917       METHODS FOR TREATING VASCULAR LEAK SYNDROME
Russian Federation    2014146121    01/12/2010          METHODS FOR TREATING VASCULAR LEAK SYNDROME
Singapore    201104563-0    01/12/2010    172312    04/19/2017    METHODS FOR TREATING VASCULAR LEAK SYNDROME
Singapore    10201702247S    01/12/2010          METHODS FOR TREATING VASCULAR LEAK SYNDROME
South Africa    2011/05679    01/12/2010    2011/05679    04/25/2012    METHODS FOR TREATING VASCULAR LEAK SYNDROME
Thailand    1101001105    01/12/2010          METHODS FOR TREATING VASCULAR LEAK SYNDROME
Vietnam    1-2011-01745    01/12/2010          COMPOUNDS THAT INHIBIT THE INTRACELLULAR CATALYTIC SITE OF PROTEIN TYROSINE PHOSPHATASE BETA (PTP-B) MOLECULE AND COMPOSITIONS COMPRISING THE SAME
United States    61/223,260    07/06/2009          COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
United States    13/783,311    03/03/2013    8,883,832    11/11/2014    COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
United States    14/272,689    05/08/2014    9,174,950    11/03/2015    COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS

 

22


United States    14/864,462    09/24/2015    9,949,956    04/24/2018    COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
United States    15/913,392    03/06/2018          COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
United States    16/582,619    09/25/2019          COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
United States    12/677,550    12/01/2010    8,569,348    10/29/2013    COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
WO    PCT/US2010/020822    01/12/2010          COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Europe    10797461.0    01/12/2010    2451279    03/13/2019    COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Europe    19159755.8    01/12/2010          COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Germany    10797461.0    01/12/2010    60 2010
057 581.0
   03/13/2019    COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
France    10797461.0    01/12/2010    2451279    03/13/2019    COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS

 

23


United Kingdom    10797461.0    01/12/2010    2451279    03/13/2019    COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Austria    10797461.0    01/12/2010    2451279    03/13/2019    COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Belgium    10797461.0    01/12/2010    2451279    03/13/2019    COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Switzerland    10797461.0    01/12/2010    2451279    03/13/2019    COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Denmark    10797461.0    01/12/2010    2451279    03/13/2019    COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Spain    10797461.0    01/12/2010    2451279    03/13/2019    COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Finland    10797461.0    01/12/2010    2451279    03/13/2019    COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Ireland    10797461.0    01/12/2010    2451279    03/13/2019    COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Italy    10797461.0    01/12/2010    2451279    03/13/2019    COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS

 

24


Netherlands    10797461.0    01/12/2010    2451279    03/13/2019    COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Norway    10797461.0    01/12/2010    2451279    03/13/2019    COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Poland    10797461.0    01/12/2010    2451279    03/13/2019    COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Portugal    10797461.0    01/12/2010    2451279    03/13/2019    COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Sweden    10797461.0    01/12/2010    2451279    03/13/2019    COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Turkey    10797461.0    01/12/2010    2451279    03/13/2019    COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Australia    2010271105    01/12/2010    2010271105    08/28/2014    COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Brazil    PI 1006897-0    01/12/2010          COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Canada    2,748,765    01/12/2010    2,748,765    07/22/2014    COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS

 

25


China    201080012192.8    01/12/2010          COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
China    201410144271.4    01/12/2010          COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
China    201510713404.X    01/12/2010          COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Hong Kong    12105753.2    01/12/2010          COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Israel    214048    01/12/2010    214048    03/01/2017    COMPOSITIONS FOR PREVENTING METASTASIS OF MELANOMA OR LUNG CANCER
Israel    248514    01/12/2010          COMPOSITIONS FOR PREVENTING METASTASIS OF MELANOMA OR LUNG CANCER
India    5406/DELNP/
2011
   01/12/2010          COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Indonesia    W00201102788    01/12/2010    IDP000045935    05/18/2017    COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Japan    2011-554058    01/12/2010    5536113    05/09/2014    COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS

 

26


Japan    2014-048238    01/12/2010          COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Japan    2015-183047    01/12/2010          COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Japan    2017-80657    01/12/2010    6505153    04/05/2019    COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Japan    2019-58234    01/12/2010          COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Korea    2011-7018742    01/12/2010    10-1426125    07/28/2014    COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Malaysia    PI 2011003556    01/12/2010    MY-160399-A    03/15/2017    COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Mexico    MX/a/2011/007420    01/12/2010    328717    03/20/2015    COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
New Zealand    594537    01/12/2010    594537    05/01/2014    COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Philippines    1-2011-501370    01/12/2010    1-2011-501370    07/21/2017    COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Russian Federation    2011133835    01/12/2010    2519123       COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS

 

27


Singapore    201104564-8    01/12/2010          COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Singapore    10201505672T    01/12/2010          COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
South Africa    2011/05678    01/12/2010    2011/05678    04/25/2012    COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Thailand    1101001097    01/12/2010          COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Vietnam    1-2011-01744    01/12/2010          COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
United States    61/390,899    10/07/2010          COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA AND NEOVASCULAZATION AND RELATED DISEASES
United States    13/253,397    10/05/2011          COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA AND NEOVASCULAZATION AND RELATED DISEASES
United States    14/300,385    01/10/2014          COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES
United States    15/462,326    03/17/2017          COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES

 

28


United States    16/513,103    07/16/2019          COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES
United States    17/352,698    06/21/2021          COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES
United States    15/796,293    10/27/2017          PHOSPHATASE INHIBITORS FOR TREATING OCULAR DISEASES
WO    PCT/US2011/054873    10/05/2011          COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA AND NEOVASCULAZATION AND RELATED DISEASES
Europe    11831498.8    10/05/2011    2624916    01/17/2018    COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES
Germany    11831498.8    10/05/2011    2624916    01/17/2018    COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES
France    11831498.8    10/05/2011    2624916    01/17/2018    COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES
United Kingdom    11831498.8    10/05/2011    2624916    01/17/2018    COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES
Ireland    11831498.8    10/05/2011    2624916    01/17/2018    COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES

 

29


Australia    2011312203    10/05/2011    2011312203    11/10/2016    COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES
Australia    2016204410    10/05/2011    2016204410    01/17/2019    COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES
Brazil    BR112013008452-9    10/05/2011          COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES
Canada    2,818,215    10/05/2011    2,818,215    07/21/2015    COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES
Canada    2,890,554    10/05/2011          COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES
China    201180059165.0    10/05/2011          COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES
China    201610996050.9    10/05/2011          COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES
Hong Kong    14101185.7    10/05/2011          COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES
Israel    229786    10/05/2011    229786    05/29/2017    COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES

 

30


Japan    2013-532904    10/05/2011          COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES
Japan    2015-182301    10/05/2011          COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES
Japan    2015-182302    10/05/2011    6243882    11/17/2017    COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES
Japan    2017-217317    10/05/2011          COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES
Korea    10-2013-
7011704
   10/05/2011          COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES
Korea    10-2015-
7002121
   10/05/2011    1823924    01/25/2018    COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES
Malaysia    PI
2013000970
   10/05/2011    MY-176514-A    08/12/2020    COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES
Mexico    MX/a/
2013/003890
   10/05/2011          COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES
Mexico    MX/a/
2017/006194
   10/05/2011    361520    12/06/2018    COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES

 

31


New Zealand    610230    10/05/2011    610230    11/03/2015    COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES
New Zealand    705624    10/05/2011    705624    01/05/2017    COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES
Philippines    1-2013-500577    10/05/2011    1-2013-500577    06/14/2019    COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES
Russian Federation    2013120064    10/05/2011    2600794    10/04/2016    COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES
Singapore    2013023809    10/05/2011    189177    11/16/2015    COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA AND NEOVASCULAZATION AND RELATED DISEASES
South Africa    2013/03005    10/05/2011    2013/03005    01/29/2014    COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES
Thailand    1301001776    10/05/2011          COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA AND NEOVASCULAZATION AND RELATED DISEASES
United States    61/792,679    03/15/2013          COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES
United States    61/792,868    03/15/2013          COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES
United States    61/882,048    09/25/2013          COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES

 

32


United States    61/882,056    09/25/2013          COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES
United States    61/934,570    01/31/2014          COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES
United States    13/999,670    03/14/2014    9,440,963    09/13/2016    COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
United States    14/214,413    03/14/2014          COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES
United States    15/098,955    04/14/2016          COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
United States    15/099,161    04/14/2016          COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
United States    15/355,910    11/18/2016    10,220,048    03/05/2019    COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
United States    15/443,622    02/27/2017          COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
United States    15/958,346    04/20/2018          COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
United States    15/958,355    04/20/2018          COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
United States    15/958,358    04/20/2018          COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES

 

33


United States    15/969,109    05/02/2018          COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
United States    16/257,287    01/25/2019          COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES
United States    16/559,006    09/03/2019          COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
United States    16/888,247    05/29/2020          COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
United States    17/155,463    01/22/2021          COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
WO    PCT/US2014/029723    03/14/2014          COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Europe    14762974.5    03/14/2014    2967066    10/23/2019    COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Europe    19174479.6    03/14/2014          COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Germany    14762974.5    03/14/2014    602014055602.7    10/23/2019    COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
France    14762974.5    03/14/2014    2967066    10/23/2019    COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
United Kingdom    1411935.8    03/14/2014    GB2516561    03/09/2016    COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES

 

34


United Kingdom    1520656.8    03/14/2014    2540638    01/17/2018    COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
United Kingdom    1709419.4    03/14/2014    2549865    01/17/2018    COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
United Kingdom    14762974.5    14-Mar-2014    2967066    10/23/2019    COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Spain    14762974.5    14-Mar-2014    2967066    10/23/2019    COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Ireland    14762974.5    03/14/2014    2967066    10/23/2019    COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Italy    14762974.5    03/14/2014    2967066    10/23/2019    COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Australia    2014233363    03/14/2014    2014233363    10/12/2017    COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Australia    2017235953    03/14/2014          COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Brazil    1120150237533    03/14/2014          COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Canada    2,903,871    03/14/2014          COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
China    201480028572.9    03/14/2014    105307498    04/16/2019    COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES

 

35


China    201910221542.4    03/14/2014          COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Israel    240786    03/14/2014    240786    11/01/2019    COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
India    9436/DELNP/2015    03/14/2014          COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Indonesia    P00201506598    03/14/2014          COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Israel    267997    03/14/2014          COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Japan    2016-503207    03/14/2014    6,572,201    08/16/2019    COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Japan    2019-147238    03/14/2014    6865254    04/07/2021    COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Japan    2021-64106    03/14/2014          COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Korea    10-2015-7029411    03/14/2014          COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Malaysia    PI 2015002288    03/14/2014    MY-171945-A    11/08/2019    COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES

 

36


Malaysia    PI2019000040    03/14/2014          COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Mexico    MX/a/2015/011131    03/14/2014    371382    01/28/2020    COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Mexico    MX/a/2020/001060    03/14/2014          COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
New Zealand    712694    03/14/2014          COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
New Zealand    750667    03/14/2014          COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Philippines    1-2015-502153    03/14/2014    1-2015-502153    11/12/2019    COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Philippines    1-2019-502018    03/14/2014          COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Singapore    11201507131W    03/14/2014          COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
South Africa    2015/07387    03/14/2014          COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
South Africa    2020/00522    03/14/2014          COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Thailand    1501005287    03/14/2014          COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES

 

37


United States    61/953,680    03/14/2014          HPTP-BETA INHIBITORS
United States    14/657,276    03/14/2014    9,994,560    06/12/2018    HPTP-BETA INHIBITORS
United States    15/972,863    05/07/2018    10,858,354    12/08/2020    HPTP-BETA INHIBITORS
United States    17/062,098    10/02/2020          HPTP-BETA INHIBITORS
WO    PCT/US2015/020425    03/13/2015          HPTP-BETA INHIBITORS
Europe    15760687.2    03/13/2015          HPTP-BETA INHIBITORS
China    201580026210.0    03/13/2015          HPTP-BETA INHIBITORS
Japan    2016-556997    3/13/2015    6483148    02/22/2019    HPTP-BETA INHIBITORS
Japan    2018-246712    3/13/2015    6661744    02/14/2020    HPTP-BETA INHIBITORS
Japan    2019-77696    04/16/2019          HPTP-BETA INHIBITORS
United States    62/034,695    08/07/2014          COMBINATION OF IMMUNOTHERAPIES WITH ACTIVATORS OF TIE-2
United States    14/819,871    08/06/2015    9,539,245    01/10/2017    COMBINATION OF IMMUNOTHERAPIES WITH ACTIVATORS OF TIE-2
United States    15/365,186    11/30/2016          COMBINATION OF IMMUNOTHERAPIES WITH ACTIVATORS OF TIE-2
WO    PCT/US2015/044030    08/06/2015          COMBINATION OF IMMUNOTHERAPIES WITH ACTIVATORS OF TIE-2
United States    62/019,002    06/30/2014          METHODS OF TREATING SEXUAL DISORDERS WITH ACTIVATORS OF TIE-2

 

38


United States    62/190,871    07/10/2015          METHODS OF TREATING SEXUAL DISORDERS WITH ACTIVATORS OF TIE-2
United States    62/361,703    07/13/2016          METHODS OF TREATING SEXUAL DISORDERS WITH ACTIVATORS OF TIE-2
United States    62/222,481    09/23/2015          METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2
United States    15/273,068    09/22/2016    10,952,992    03/23/2021    METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2
United States    17/150,430    01/15/2021          METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2
WO    PCT/US2016/053107    09/22/2016          METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2
Europe    16849594.3    09/22/2016          METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2
Australia    2016326510    09/22/2016          METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2
Brazil    1120180054992    09/22/2016          METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2
Canada    2,998,673    09/22/2016          METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2
China    201680068508.2    09/22/2016          METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2
India    201817014284    09/22/2016          METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2
Indonesia    P00201802937    09/22/2016          METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2
Israel    258150    09/22/2016          METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2

 

39


Japan    2018-534502    09/22/2016          METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2
Korea, Republic of    10-2018-7010228    09/22/2016          METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2
Malaysia    PI2018000423    09/22/2016          METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2
Mexico    MX/a/2018/003542    09/22/2016          METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2
New Zealand    740730    09/22/2016          METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2
Philippines    1-2018-500658    09/22/2016          METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2
Singapore    11201802402U    09/22/2016          METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2
Singapore    10201912000W    09/22/2016          METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2
South Africa    2018/01795    09/22/2016          METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2
United States    62/635,102    02/26/2018          METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS
United States    62/790,646    01/10/2019          METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS
United States    16/284,349    02/25/2019          METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS
United States    17/130,687    12/22/2020          METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS

 

40


WO    PCT/US2019/019366    02/25/2019          METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS
Europe    19756688.8    02/25/2019          METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS
Japan    2020-567452    02/25/2019          METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS
United States    62/835,626    04/18/2019          METHODS OF TREATING HYPERTENSION WITH ACTIVATORS OF TIE-2
United States    62/840,655    04/30/2019          METHODS OF TREATING PULMONARY HYPERTENSION USING TIE-2 ACTIVATORS
United States    16/850,613    04/16/2020          METHODS OF TREATING HYPERTENSION WITH ACTIVATORS OF TIE-2
WO    PCT/US2020/028577    04/16/2020          METHODS OF TREATING HYPERTENSION WITH ACTIVATORS OF TIE-2
United States    62/865,653    06/24/2019          FORMULATIONS OF TIE-2 ACTIVATORS AND METHODS OF USE THEREOF
United States    63/009,083    04/13/2020          FORMULATIONS OF TIE-2 ACTIVATORS AND METHODS OF USE THEREOF
United States    16/908,996    06/23/2020          FORMULATIONS OF TIE-2 ACTIVATORS AND METHODS OF USE THEREOF
United Kingdom    2009592.3    06/23/2020          FORMULATIONS OF TIE-2 ACTIVATORS AND METHODS OF USE THEREOF
United States    62/927,233    10/29/2019          SMALL MOLECULE ACTIVATORS OF TIE-2
United States    17/082,612    10/28/2020          SMALL MOLECULE ACTIVATORS OF TIE-2
WO    PCT/US2020/057641    10/28/2020          SMALL MOLECULE ACTIVATORS OF TIE-2
United States    62/840,068    04/29/2019          TIE-2 ACTIVATORS TARGETING SCHLEMM’S CANAL

 

41


United States    16/860,347    04/28/2020          TIE-2 ACTIVATORS TARGETING SCHLEMM’S CANAL
WO    PCT/US2020/030224    04/28/2020          TIE-2 ACTIVATORS TARGETING THE SCHLEMM’S CANAL
United States    62/958,348    01/08/2020          COMBINATIONS OF TIE-2 ACTIVATORS AND PROSTAGLANDINS AND USES THEREOF
United States    63/089,144    10/08/2020          COMBINATIONS OF TIE-2 ACTIVATORS AND PROSTAGLANDINS AND USES THEREOF
United States    17/143,394    01/07/2021          COMBINATIONS OF TIE-2 ACTIVATORS AND PROSTAGLANDINS AND USES THEREOF
WO    PCT/US2021/012407    01/07/2021          COMBINATIONS OF TIE-2 ACTIVATORS AND PROSTAGLANDINS AND USES THEREOF
United States    63/127,412    12/18/2020          DOSAGE FORMS OF TIE-2 ACTIVATORS
United States    63/127,411    12/18/2020          METHODS FOR MANUFACTURE OF SMALL ACTIVATORS OF TIE-2
United States    63/028,317    05/21/2020          METHODS OF TREATING ACUTE RESPIRATORY DISTRESS SYNDROME WITH ACTIVATORS OF TIE-2
WO    PCT/US2021/033495    05/20/2021          METHODS OF TREATING ACUTE RESPIRATORY DISTRESS SYNDROME WITH ACTIVATORS OF TIE-2

Group 2

 

Country

   Application No.    Filing
Date
   Patent No.    Patent
Date
  

Title

United States    60/790,506    04/07/2006          ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA)
United States    60/798,896    05/09/2006          ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA)

 

42


United States    11/784,094    04/05/2007    7,973,142    07/05/2011    ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA)
United States    15/430,100    02/10/2017    9,926,367    03/27/2018    ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
United States    15/894,442    02/12/2018          ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
United States    16/696,212    11/26/2019          ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
United States    16/784,970    02/07/2020          ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE beta (HPTPbeta) AND USES THEREOF
United States    13/115,180    05/25/2011    8,524,235    09/03/2013    ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA)
United States    13/958,990    08/05/2013          ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA)
WO    PCT/
IB2007/051239
   04/05/2007          ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA)
Europe    07735408.2    04/05/2007          ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF

 

43


Europe    11155518.1    04/05/2007    2371865    07/12/2017    ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Europe    17169315.3    04/05/2017    3252079    07/29/2020    ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
United Arab Emirates    978/2008    04/05/2007          ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Austria    11155518.1    04/05/2007    2371865    07/12/2017    ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Australia    2007237096    04/05/2007    2007237096    12/20/2012    ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Belgium    11155518.1    04/05/2007    2371865    07/12/2017    ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Brazil    PI 0710645-9    04/05/2007          ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Canada    2,648,284    04/05/2007    2,648,284    08/16/2016    ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Switzerland    11155518.1    04/05/2007    2371865    07/12/2017    ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF

 

44


China    200780011778.0    04/05/2007    ZL 200780011778.0    08/31/2016    ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
China    201610648805.6    04/05/2007          ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Colombia    08-105786    04/05/2007    4311    08/24/2012    ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Germany    602007051642.0    04/05/2007    2371865    07/12/2017    ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Germany    602007060503.2    04/05/2017    3252079    07/29/2020    ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Denmark    11155518.1    04/05/2007    2371865    07/12/2017    ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Egypt    1612/2008    04/05/2007          ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Spain    11155518.1    04/05/2007    2371865    07/12/2017    ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Spain    17169315.3    04/05/2017    3252079    07/29/2020    ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF

 

45


Finland    11155518.1    04/05/2007    2371865    07/12/2017    ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
France    11155518.1    04/05/2007    2371865    07/12/2017    ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
France    17169315.3    04/05/2017    3252079    07/29/2020    ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
United Kingdom    11155518.1    04/05/2007    2371865    07/12/2017    ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
United Kingdom    17169315.3    04/05/2017    3252079    07/29/2020    ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Indonesia    W00200803006    04/05/2007    IDP000051812    07/10/2018    ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Ireland    11155518.1    04/05/2007    2371865    07/12/2017    ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Israel    194550    04/05/2007    194550    10/01/2015    ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Israel    239320    04/05/2007    239320    05/01/2019    ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF

 

46


Israel    263755    04/05/2007          ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
India    8043/DELNP/2008    04/05/2007    271047    01/29/2016    ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Italy    11155518.1    04/05/2007    2371865    07/12/2017    ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Italy    17169315.3    04/05/2017    3252079    07/29/2020    ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Japan    2009-503719    04/05/2007    5166398    12/28/2012    ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Japan    2012-223157    04/05/2007          ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Japan    2015-107275    04/05/2007          ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Japan    2016-226664    04/05/2007    6395791    09/07/2018    ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Japan    2017-131042    04/05/2007          ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF

 

47


Japan    2018-246735    04/05/2007          ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Korea    10-2008-7026944    04/05/2007          ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Korea    10-2011-7024995    04/05/2007          ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Korea    10-2013-7022106    04/05/2007    1482483    01/07/2015    ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Morocco    PV/31325    04/05/2007    30353    04/01/2009    ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Mexico    MX/a/2008/012991    04/05/2007    295062    01/23/2012    ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Malaysia    PI 20080003870    04/05/2007    MY-150400-A    01/15/2014    ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Netherlands    11155518.1    04/05/2007    2371865    07/12/2017    ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
New Zealand    571300    04/05/2007    571300    04/02/2012    ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF

 

48


Philippines    1-2008-502246    04/05/2007          ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Poland    11155518.1    04/05/2007    2371865    07/12/2017    ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Portugal    11155518.1    04/05/2007    2371865    07/12/2017    ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Russia    2008138399    04/05/2007    2473565    01/27/2013    ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Russia    2011141686    04/05/2007    2494108    09/27/2013    ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Sweden    11155518.1    04/05/2007    2371865    07/12/2017    ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Singapore    200806979-1    04/05/2007          ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Singapore    201102498-1    04/05/2007    170842    04/09/2015    ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
San Marino    P-200800060    04/05/2007    SM-AP-200800060       ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF

 

49


Turkey    11155518.1    04/05/2007    2371865    07/12/2017    ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Vietnam    1-2008-02466    04/05/2007    14457    08/17/2015    ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
South Africa    2008/07978    04/05/2007    2008/07978    08/26/2009    ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
United States    61/546,708    10/13/2011          TREATMENT OF OCULAR DISEASE
United States    13/652,154    10/15/2012    8,999,325    04/07/2015    TREATMENT OF OCULAR DISEASE
United States    14/627,463    02/20/2015          TREATMENT OF OCULAR DISEASES
United States    15/463,340    03/20/2017    10,329,357    06/25/2019    TREATMENT OF OCULAR DISEASES
United States    16/395,972    04/26/2019          TREATMENT OF OCULAR DISEASES
United States    16/751,824    01/24/2020          TREATMENT OF OCULAR DISEASES
WO    PCT/US2012/060263    10/15/2012          TREATMENT OF OCULAR DISEASE
Europe    12840725.1    10/15/2012    2766044    12/11/2019    TREATMENT OF OCULAR DISEASE
Europe    18202143.6    10/15/2012          TREATMENT OF OCULAR DISEASE
Australia    2012323849    10/15/2012    2012323849    08/03/2017    TREATMENT OF OCULAR DISEASE
Brazil    112014008759-8    10/15/2012          TREATMENT OF OCULAR DISEASE
Canada    2,850,824    10/15/2012          TREATMENT OF OCULAR DISEASE

 

50


China    201280054482.8    10/15/2012          TREATMENT OF OCULAR DISEASE
China    201710084072.2    10/15/2012          TREATMENT OF OCULAR DISEASE
Germany    12840725.1    10/15/2012    602012066453.3    12/11/2019    TREATMENT OF OCULAR DISEASE
Spain    12840725.1    10/15/2012    2766044    12/11/2019    TREATMENT OF OCULAR DISEASE
France    12840725.1    10/15/2012    2766044    12/11/2019    TREATMENT OF OCULAR DISEASE
United Kingdom    12840725.1    10/15/2012    2766044    12/11/2019    TREATMENT OF OCULAR DISEASE
Hong Kong    15101784.1    10/15/2012          TREATMENT OF OCULAR DISEASE
Hong Kong    15101828.9    10/15/2012          TREATMENT OF OCULAR DISEASE
Ireland    12840725.1    10/15/2012    2766044    12/11/2019    TREATMENT OF OCULAR DISEASE
Italy    12840725.1    10/15/2012    2766044    12/11/2019    TREATMENT OF OCULAR DISEASE
Japan    2014-535978    10/15/2012          TREATMENT OF OCULAR DISEASE
Japan    2016-178592    10/15/2012    6259503    12/15/2017    TREATMENT OF OCULAR DISEASE
Japan    2016-178593    10/15/2012          TREATMENT OF OCULAR DISEASE
Japan    2018-103592    10/15/2012          TREATMENT OF OCULAR DISEASE
Japan    2018-103593    10/15/2012          TREATMENT OF OCULAR DISEASE
Mexico    MX/a/2014/004449    10/15/2012    347226    04/19/2017    TREATMENT OF OCULAR DISEASE
New Zealand    623275    10/15/2012    623275    08/30/2016    TREATMENT OF OCULAR DISEASE

 

51


United States    61/546,697    10/13/2011          METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
United States    61/546,748    10/13/2011          METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
United States    13/652,203    10/15/2012          METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
United States    15/438,218    02/21/2017    10,150,811    12/11/2018    METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
United States    16/168,060    10/23/2018    10,815,300    10/27/2020    METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
United States    17/027,034    09/21/2020          METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
WO    PCT/US2012/060273    10/15/2012          METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
Europe    12840220.3    10/15/2012          METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
Europe    18201774.9    10/15/2012          METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
Australia    2012323856    10/15/2012    2012323856    09/07/2017    METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
Brazil    112014008819-5    10/15/2012          METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
Canada    2,850,830    10/15/2012          METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
China    201280052307.5    10/15/2012          METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER

 

52


China    201910768287.5    10/15/2012          METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
Hong Kong    15101641.4    10/15/2012          METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
Japan    2014-535979    10/15/2012          METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
Japan    2017-130652    10/15/2012          METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
Japan    2017-143622    07/25/2017          METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
Japan    2019-87483    10/15/2012    6706367    05/19/2020    METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
Japan    2019-115666    10/15/2012          METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
Mexico    MX/a/2014/004448    10/15/2012    363351    03/20/2019    METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
Mexico    MX/a/2019/002983    10/15/2012          METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
New Zealand    623283    10/15/2012    623283    08/30/2016    METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
United States    62/054,752    24-Sep-2014          VE-PTP EXTRACELLULAR DOMAIN ANTIBODIES DELIVERED BY A GENE THERAPY
United States    14/862,948    09/23/2015          VE-PTP EXTRACELLULAR DOMAIN ANTIBODIES DELIVERED BY A GENE THERAPY
United States    15/815,097    11/16/2017          VE-PTP EXTRACELLULAR DOMAIN ANTIBODIES DELIVERED BY A GENE THERAPY
WO    PCT/US2015/051719    09/23/2015          VE-PTP EXTRACELLULAR DOMAIN ANTIBODIES DELIVERED BY A GENE THERAPY

 

53


United States    62/364,381    07/20/2016          HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP
United States    62/377,072    08/19/2016          HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP
United States    15/654,289    07/19/2017    10,253,094    04/09/2019    HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP (HPTP-Beta)
United States    16/180,850    11/05/2018    10,604,569    03/31/2020    HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-Beta)
United States    16/180,854    11/05/2018    10,597,452    03/24/2020    HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-Beta)
United States    16/775,860    01/29/2020          HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-Beta)
United States    16/851,420    04/17/2020          HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-Beta)
Europe    17831790.5    07/19/2017          HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP
WO    PCT/US2017/042855    07/19/2017          HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP
Australia    2017299581    07/19/2017          HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP
Brazil    1120190012060    07/19/2017          HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP
Canada    3,030,298    07/19/2017          HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP

 

54


China    201780057896.9    07/19/2017          HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP
Indonesia    PID201900449    07/19/2017          HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP
Israel    263936    07/19/2017          HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP
India    201817049429    07/19/2017          HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP
Japan    2019-502696    07/19/2017          HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP
Japan    2020-120521    07/19/2017          HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP (HPTP-ß)
Korea    10-2019-7002479    07/19/2017          HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP
Mexico    MX/a/2019/000727    07/19/2017          HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP
Malaysia    PI2019000120    07/19/2017          HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP
New Zealand    749494    07/19/2017          HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP
Philippines    1-2019-500145    07/19/2017          HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP
Singapore    11201900464T    07/19/2017          HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP
Singapore    10201912556V    07/19/2017          HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP

 

55


South Africa    2019/00368    07/19/2017          HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP
South Africa    2020/01991    07/19/2017          HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)

Group 3

 

Country

   Application No.    Filing
Date
   Patent
No.
   Patent
Date
  

Title

United States    62/735,331    09/24/2018          BISPECIFIC ANTIBODIES THAT TARGET VE-PTP (HPTP-B) AND VEGF
United States    62/832,461    04/11/2019          MULTISPECIFIC ANTIBODIES THAT TARGET HPTP-B (VE-PTP) AND VEGF
United States    16/579,078    09/23/2019    10,894,824    01/19/2021    MULTISPECIFIC ANTIBODIES THAT TARGET HPTP-B (VE-PTP) AND VEGF
United States    17/117,993    12/10/2020          MULTISPECIFIC ANTIBODIES THAT TARGET HPTP-B (VE-PTP) AND VEGF
WO    PCT/US2019/052405    09/23/2019          MULTISPECIFIC ANTIBODIES THAT TARGET HPTP-B (VE-PTP) AND VEGF
Europe    19867311.3    09/23/2019          MULTISPECIFIC ANTIBODIES THAT TARGET HPTP-B (VE-PTP) AND VEGF
China    201980077336.9    09/23/2019          MULTISPECIFIC ANTIBODIES THAT TARGET HPTP-B (VE-PTP) AND VEGF
Japan    2021-516373    09/23/2019          MULTISPECIFIC ANTIBODIES THAT TARGET HPTP-ß (VE-PTP) AND VEGF

 

56


EXHIBIT C

MATERIALS

[Omitted pursuant to Item 601(a)(5) of Regulation S-K]

 

57


EXHIBIT D

PATENT ASSIGNMENT

[Omitted pursuant to Item 601(a)(5) of Regulation S-K]

 

58


EXHIBIT E

JOINT ESCROW INSTRUCTIONS

[Omitted pursuant to Item 601(a)(5) of Regulation S-K]

 

59


EXHIBIT F-1

IND TRANSFER LETTER (#1)

[Omitted pursuant to Item 601(a)(5) of Regulation S-K]

 

60


EXHIBIT F-2

IND TRANSFER LETTER (#2)

[Omitted pursuant to Item 601(a)(5) of Regulation S-K]

 

61